JP2012526844A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526844A5
JP2012526844A5 JP2012511013A JP2012511013A JP2012526844A5 JP 2012526844 A5 JP2012526844 A5 JP 2012526844A5 JP 2012511013 A JP2012511013 A JP 2012511013A JP 2012511013 A JP2012511013 A JP 2012511013A JP 2012526844 A5 JP2012526844 A5 JP 2012526844A5
Authority
JP
Japan
Prior art keywords
nifedipine
composition
item
nitrosonifedipine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012511013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526844A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Publication of JP2012526844A publication Critical patent/JP2012526844A/ja
Publication of JP2012526844A5 publication Critical patent/JP2012526844A5/ja
Pending legal-status Critical Current

Links

JP2012511013A 2009-05-15 2010-05-13 Mciおよびアルツハイマー病の処置 Pending JP2012526844A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21645209P 2009-05-15 2009-05-15
US61/216,452 2009-05-15
US23455109P 2009-08-17 2009-08-17
US61/234,551 2009-08-17
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2012526844A JP2012526844A (ja) 2012-11-01
JP2012526844A5 true JP2012526844A5 (cg-RX-API-DMAC7.html) 2013-06-27

Family

ID=43069025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012511013A Pending JP2012526844A (ja) 2009-05-15 2010-05-13 Mciおよびアルツハイマー病の処置

Country Status (7)

Country Link
US (1) US20100292281A1 (cg-RX-API-DMAC7.html)
EP (1) EP2429992A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012526844A (cg-RX-API-DMAC7.html)
AU (1) AU2010249015A1 (cg-RX-API-DMAC7.html)
CA (1) CA2761298A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011012015A (cg-RX-API-DMAC7.html)
WO (1) WO2010132671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2013022953A2 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
MX2014015310A (es) * 2012-06-15 2015-07-06 Found Biomedical Res & Innov Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR102149321B1 (ko) * 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
EP3684348A4 (en) * 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
EP1069918A4 (en) * 1998-04-08 2002-02-20 Univ Oregon Health Sciences ACTIVATION OF THE CELLULAR RECORDING OF THE GALLIUM
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
AU2004292966A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
EP1955698B1 (en) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Icam−1発現抑制剤

Similar Documents

Publication Publication Date Title
JP2012526844A (ja) Mciおよびアルツハイマー病の処置
JP2013526518A (ja) Mciおよびアルツハイマー病の処置
US20180325862A1 (en) Methods for treating alzheimer?s disease and related disorders
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
Takahashi-Ito et al. Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates
JP2013526518A5 (cg-RX-API-DMAC7.html)
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
ES2334029T3 (es) Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
KR101417200B1 (ko) (-)-닐바디핀 거울상이성질체를 사용하여 아밀로이드 침착, 아밀로이드 신경독성 및 소교세포증을 감소시키는 방법
Samentar et al. A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
Lovell et al. Treatment of MCI and Alzheimer's Disease
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
HK1212603A1 (zh) 治疗阿尔茨海默病及相关疾病的组合疗法